IMVT · Immunovant, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $101.20M | $98.92M | $114.25M | $75.47M | $94.52M | $97.27M | $28.43M | $48.34M | $47.96M | $28.43M |
| SG&A | $26.02M | $15.44M | $17.51M | $18.81M | $19.78M | $18.47M | $15.40M | $13.21M | $13.84M | $11.95M |
| Total Operating Expenses | $127.22M | $114.36M | $131.76M | $94.28M | $114.30M | $115.74M | $78.48M | $61.55M | $61.80M | $40.38M |
| D&A | $107.0K | - | - | $80.0K | - | - | $53.0K | - | - | $44.0K |
| Operating Income | ($119.70M) | ($109.08M) | ($125.91M) | ($87.07M) | ($110.97M) | ($109.04M) | ($73.95M) | ($51.53M) | ($58.21M) | ($40.02M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $913.0K | $1.55M | $594.0K | $77.0K | $152.0K | $78.0K | ($11.0K) | ($108.0K) | $454.0K | $352.0K |
| Net Income | ($120.61M) | ($110.64M) | ($126.50M) | ($87.15M) | ($111.12M) | ($109.12M) | ($73.94M) | ($51.42M) | ($58.66M) | ($40.37M) |
| EPS - Basic | ($0.71) | ($0.61) | ($0.73) | ($0.60) | ($0.76) | ($0.74) | ($0.57) | ($0.36) | ($0.45) | ($0.35) |
| EPS - Diluted | ($0.71) | ($0.61) | ($0.73) | ($0.60) | ($0.76) | ($0.74) | ($0.57) | ($0.36) | ($0.45) | ($0.35) |
Balance Sheet
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $902.11M | $994.52M | $521.87M | $713.97M | $374.69M | $472.94M | $635.37M | $690.94M | $269.93M | $376.53M |
| Accounts Receivable | $1.13M | $1.64M | $1.97M | $2.08M | $2.22M | $1.88M | $5.34M | $1.03M | $1.42M | $700.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $7.54M | $8.62M | $6.92M | $17.66M | $19.82M | $20.73M | $7.16M | $3.91M | $7.51M | $1.35M |
| Current Assets | $948.82M | $1.04B | $573.55M | $767.66M | $412.54M | $507.37M | $665.77M | $710.78M | $291.18M | $404.33M |
| Total Assets | $957.01M | $1.05B | $582.96M | $776.22M | $420.93M | $515.71M | $666.37M | $711.45M | $292.07M | $405.84M |
| Current Liabilities | $104.42M | $66.26M | $63.25M | $68.78M | $68.31M | $66.65M | $48.61M | $32.10M | $40.26M | $43.30M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $104.42M | $66.26M | $63.25M | $68.78M | $68.31M | $66.65M | $48.61M | $32.10M | $40.26M | $43.34M |
| Stockholders' Equity | $852.59M | $986.13M | $519.71M | $707.45M | $352.62M | $449.05M | $617.76M | $679.34M | $251.81M | $362.49M |
| Retained Earnings | ($1.75B) | ($1.60B) | ($1.49B) | ($1.24B) | ($1.13B) | ($1.02B) | ($825.68M) | ($750.36M) | ($698.95M) | ($566.35M) |
Cash Flow
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($117.41M) | - | - | ($76.20M) | - | - | ($47.37M) | - | - | ($65.82M) |
| Investing Cash Flow | $0 | - | - | ($182.0K) | - | - | ($45.0K) | - | - | ($42.0K) |
| Financing Cash Flow | $2.92M | - | - | $686.0K | - | - | $890.0K | - | - | $21.0K |
| CapEx | $0 | - | - | $182.0K | - | - | $45.0K | - | - | $42.0K |
| Free Cash Flow | ($117.41M) | - | - | ($76.38M) | - | - | ($47.41M) | - | - | ($65.86M) |
Ratios
| Metric | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.97 | - | - | 0.88 | - | - | 0.64 | - | - | 1.63 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.6% | -10.5% | -21.7% | -11.2% | -26.4% | -21.2% | -11.1% | -7.2% | -20.1% | -9.9% |
| Return on equity | -14.1% | -11.2% | -24.3% | -12.3% | -31.5% | -24.3% | -12.0% | -7.6% | -23.3% | -11.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 9.09 | 15.74 | 9.07 | 11.16 | 6.04 | 7.61 | 13.70 | 22.14 | 7.23 | 9.34 |
| Quick ratio | 9.09 | 15.74 | 9.07 | 11.16 | 6.04 | 7.61 | 13.70 | 22.14 | 7.23 | 9.34 |
| Cash ratio | 8.64 | 15.01 | 8.25 | 10.38 | 5.48 | 7.10 | 13.07 | 21.52 | 6.70 | 8.70 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.12 | 1.07 | 1.12 | 1.10 | 1.19 | 1.15 | 1.08 | 1.05 | 1.16 | 1.12 |
| Liabilities / Assets | 0.11 | 0.06 | 0.11 | 0.09 | 0.16 | 0.13 | 0.07 | 0.05 | 0.14 | 0.11 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 5.0x | 4.7x | 5.4x | 3.5x | 10.3x | 9.3x | 6.8x | 9.0x | 20.0x | 5.0x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -37.5% | 1.7% | -15.5% | -17.7% | -115.4% | -87.3% | -84.8% | 18.0% | -22.1% | - |
| Net income growth (YoY) | -38.4% | 0.4% | -15.9% | -17.9% | -116.1% | -86.0% | -83.1% | 18.7% | -22.4% | - |
| EPS growth (YoY) | -18.3% | 19.7% | 1.4% | -5.3% | -111.1% | -64.4% | -62.9% | 26.5% | -9.8% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -53.7% | - | - | -61.1% | - | - | 28.0% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 20.5% | 179.7% | 15.7% | 14.5% | -48.1% | 78.3% | 70.4% | 63.8% | -36.4% | -22.8% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Immunovant against the 5 most active filers in the same SIC group.